Published in Proc Natl Acad Sci U S A on September 19, 2003
Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature (2010) 23.55
ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell (2007) 22.89
Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer (2009) 14.17
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
The Polycomb complex PRC2 and its mark in life. Nature (2011) 11.97
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet (2010) 10.97
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Regulation of chromatin by histone modifications. Cell Res (2011) 8.44
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Suz12 is essential for mouse development and for EZH2 histone methyltransferase activity. EMBO J (2004) 7.32
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature (2012) 7.01
Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Res (2006) 6.75
Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev (2007) 6.71
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Covalent histone modifications--miswritten, misinterpreted and mis-erased in human cancers. Nat Rev Cancer (2010) 6.27
The Polycomb Ezh2 methyltransferase regulates muscle gene expression and skeletal muscle differentiation. Genes Dev (2004) 6.20
Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev (2004) 6.19
Histone methylation: a dynamic mark in health, disease and inheritance. Nat Rev Genet (2012) 5.42
Novel mutations target distinct subgroups of medulloblastoma. Nature (2012) 4.82
Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med (2010) 4.81
Composition and histone substrates of polycomb repressive group complexes change during cellular differentiation. Proc Natl Acad Sci U S A (2005) 4.57
Coordinated activities of wild-type plus mutant EZH2 drive tumor-associated hypertrimethylation of lysine 27 on histone H3 (H3K27) in human B-cell lymphomas. Proc Natl Acad Sci U S A (2010) 4.52
Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer (2009) 4.40
Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell (2010) 4.18
Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation. Blood (2010) 4.02
The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med (2013) 3.96
The SET-domain protein superfamily: protein lysine methyltransferases. Genome Biol (2005) 3.93
Repression of E-cadherin by the polycomb group protein EZH2 in cancer. Oncogene (2008) 3.92
A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol (2012) 3.89
CXCR7 (RDC1) promotes breast and lung tumor growth in vivo and is expressed on tumor-associated vasculature. Proc Natl Acad Sci U S A (2007) 3.85
Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov (2009) 3.50
Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer. Genome Res (2011) 3.36
Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. Proc Natl Acad Sci U S A (2005) 3.24
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood (2005) 2.99
Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic transformation. Cancer Cell (2010) 2.80
Cyclin-dependent kinases regulate epigenetic gene silencing through phosphorylation of EZH2. Nat Cell Biol (2010) 2.64
Chromatin proteins and modifications as drug targets. Nature (2013) 2.60
Stem cell chromatin patterns: an instructive mechanism for DNA hypermethylation? Cell Cycle (2007) 2.55
EZH2 promotes expansion of breast tumor initiating cells through activation of RAF1-β-catenin signaling. Cancer Cell (2011) 2.54
The polycomb group protein Bmi-1 represses the tumor suppressor PTEN and induces epithelial-mesenchymal transition in human nasopharyngeal epithelial cells. J Clin Invest (2009) 2.52
Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer (2013) 2.41
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Characterization of an antagonistic switch between histone H3 lysine 27 methylation and acetylation in the transcriptional regulation of Polycomb group target genes. Nucleic Acids Res (2010) 2.37
CDK1-dependent phosphorylation of EZH2 suppresses methylation of H3K27 and promotes osteogenic differentiation of human mesenchymal stem cells. Nat Cell Biol (2010) 2.36
Downregulation of EZH2 decreases growth of estrogen receptor-negative invasive breast carcinoma and requires BRCA1. Oncogene (2008) 2.31
EZH2 is a mediator of EWS/FLI1 driven tumor growth and metastasis blocking endothelial and neuro-ectodermal differentiation. Proc Natl Acad Sci U S A (2009) 2.25
Agglomerative epigenetic aberrations are a common event in human breast cancer. Cancer Res (2008) 2.22
Integration of estrogen and Wnt signaling circuits by the polycomb group protein EZH2 in breast cancer cells. Mol Cell Biol (2007) 2.14
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood (2010) 2.11
Low levels of miR-92b/96 induce PRMT5 translation and H3R8/H4R3 methylation in mantle cell lymphoma. EMBO J (2007) 2.08
Identification of Potent, Selective, Cell-Active Inhibitors of the Histone Lysine Methyltransferase EZH2. ACS Med Chem Lett (2012) 2.04
Prognostic meta-signature of breast cancer developed by two-stage mixture modeling of microarray data. BMC Genomics (2004) 2.02
Characterization of KRAS rearrangements in metastatic prostate cancer. Cancer Discov (2011) 2.02
Loss of trimethylation at lysine 27 of histone H3 is a predictor of poor outcome in breast, ovarian, and pancreatic cancers. Mol Carcinog (2008) 2.01
Discovery of anticancer agents of diverse natural origin. Pure Appl Chem (2009) 2.00
Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J (2007) 1.99
Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101, and miR-98. Cell Death Dis (2010) 1.98
Feature selection and molecular classification of cancer using genetic programming. Neoplasia (2007) 1.94
Throwing the cancer switch: reciprocal roles of polycomb and trithorax proteins. Nat Rev Cancer (2010) 1.93
miR-101 is down-regulated in glioblastoma resulting in EZH2-induced proliferation, migration, and angiogenesis. Oncotarget (2010) 1.92
Enhancer of zeste homologue 2 (EZH2) down-regulates RUNX3 by increasing histone H3 methylation. J Biol Chem (2008) 1.92
Genomic analysis of estrogen cascade reveals histone variant H2A.Z associated with breast cancer progression. Mol Syst Biol (2008) 1.89
Cancer epigenetics: linking basic biology to clinical medicine. Cell Res (2011) 1.88
Coordinated regulation of polycomb group complexes through microRNAs in cancer. Cancer Cell (2011) 1.86
What is the malignant nature of human ductal carcinoma in situ? Nat Rev Cancer (2010) 1.86
Curcumin analogue CDF inhibits pancreatic tumor growth by switching on suppressor microRNAs and attenuating EZH2 expression. Cancer Res (2011) 1.80
Subunit contributions to histone methyltransferase activities of fly and worm polycomb group complexes. Mol Cell Biol (2005) 1.78
Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat Chem Biol (2013) 1.75
Protein arginine methyltransferase 5 suppresses the transcription of the RB family of tumor suppressors in leukemia and lymphoma cells. Mol Cell Biol (2008) 1.73
Connections between epigenetic gene silencing and human disease. Mutat Res (2007) 1.72
Mel-18, a polycomb group protein, regulates cell proliferation and senescence via transcriptional repression of Bmi-1 and c-Myc oncoproteins. Mol Biol Cell (2006) 1.67
Evaluation of histone 3 lysine 27 trimethylation (H3K27me3) and enhancer of Zest 2 (EZH2) in pediatric glial and glioneuronal tumors shows decreased H3K27me3 in H3F3A K27M mutant glioblastomas. Brain Pathol (2013) 1.64
The histone demethylase UTX enables RB-dependent cell fate control. Genes Dev (2010) 1.62
The N terminus of Drosophila ESC binds directly to histone H3 and is required for E(Z)-dependent trimethylation of H3 lysine 27. Mol Cell Biol (2007) 1.60
Clinicopathological significance of EZH2 mRNA expression in patients with hepatocellular carcinoma. Br J Cancer (2005) 1.59
Mel-18 acts as a tumor suppressor by repressing Bmi-1 expression and down-regulating Akt activity in breast cancer cells. Cancer Res (2007) 1.56
Mutations in regulators of the epigenome and their connections to global chromatin patterns in cancer. Nat Rev Genet (2013) 1.53
Myc enforces overexpression of EZH2 in early prostatic neoplasia via transcriptional and post-transcriptional mechanisms. Oncotarget (2011) 1.52
CDKN1C (p57) is a direct target of EZH2 and suppressed by multiple epigenetic mechanisms in breast cancer cells. PLoS One (2009) 1.52
Targeting EZH2 in cancer. Nat Med (2016) 1.51
HIV-1 transcription and latency: an update. Retrovirology (2013) 1.49
Inhibition of CCN6 (Wnt-1-induced signaling protein 3) down-regulates E-cadherin in the breast epithelium through induction of snail and ZEB1. Am J Pathol (2008) 1.48
Enhancer of zeste homolog 2 promotes the proliferation and invasion of epithelial ovarian cancer cells. Mol Cancer Res (2010) 1.46
EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. Cancer Res (2011) 1.46
The dual role of sirtuins in cancer. Genes Cancer (2011) 1.45
BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res (2009) 1.44
Emerging epigenetic targets and therapies in cancer medicine. Cancer Discov (2012) 1.43
ANCCA/ATAD2 overexpression identifies breast cancer patients with poor prognosis, acting to drive proliferation and survival of triple-negative cells through control of B-Myb and EZH2. Cancer Res (2010) 1.43
The Polycomb group protein EZH2 impairs DNA repair in breast epithelial cells. Neoplasia (2005) 1.42
Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. BMC Cancer (2010) 1.42
EZH2 and BMI1 inversely correlate with prognosis and TP53 mutation in breast cancer. Breast Cancer Res (2008) 1.42
De novo peptide design and experimental validation of histone methyltransferase inhibitors. PLoS One (2014) 1.42
Whole transcriptome amplification for gene expression profiling and development of molecular archives. Neoplasia (2006) 1.41
A chemical probe toolbox for dissecting the cancer epigenome. Nat Rev Cancer (2017) 1.40
Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics (2006) 1.39
Regulation of pancreatic tumor cell proliferation and chemoresistance by the histone methyltransferase enhancer of zeste homologue 2. Clin Cancer Res (2008) 1.39
Defining aggressive prostate cancer using a 12-gene model. Neoplasia (2006) 1.39
Genetic and epigenetic loss of microRNA-31 leads to feed-forward expression of EZH2 in melanoma. Oncotarget (2012) 1.36
The hallmarks of cancer. Cell (2000) 113.05
Molecular portraits of human breast tumours. Nature (2000) 94.14
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A (2001) 71.82
Gene expression profiling predicts clinical outcome of breast cancer. Nature (2002) 71.36
Gene-expression profiles in hereditary breast cancer. N Engl J Med (2001) 29.80
Role of histone H3 lysine 27 methylation in Polycomb-group silencing. Science (2002) 24.31
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Cancer statistics, 2003. CA Cancer J Clin (2003) 13.46
Histone methyltransferase activity of a Drosophila Polycomb group repressor complex. Cell (2002) 13.05
The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature (1999) 12.60
Drosophila enhancer of Zeste/ESC complexes have a histone H3 methyltransferase activity that marks chromosomal Polycomb sites. Cell (2002) 12.28
Delineation of prognostic biomarkers in prostate cancer. Nature (2001) 12.25
Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. Cancer Res (2001) 8.34
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Stabilization of chromatin structure by PRC1, a Polycomb complex. Cell (1999) 6.90
Transcriptional repression mediated by the human polycomb-group protein EED involves histone deacetylation. Nat Genet (1999) 5.58
Validation of tissue microarray technology in breast carcinoma. Lab Invest (2000) 5.50
Bmi-1 collaborates with c-Myc in tumorigenesis by inhibiting c-Myc-induced apoptosis via INK4a/ARF. Genes Dev (1999) 5.35
Mammalian homologues of the Polycomb-group gene Enhancer of zeste mediate gene silencing in Drosophila heterochromatin and at S. cerevisiae telomeres. EMBO J (1997) 5.25
The Drosophila Polycomb Group proteins ESC and E(Z) are present in a complex containing the histone-binding protein p55 and the histone deacetylase RPD3. Development (2001) 3.46
Characterization of interactions between the mammalian polycomb-group proteins Enx1/EZH2 and EED suggests the existence of different mammalian polycomb-group protein complexes. Mol Cell Biol (1998) 3.30
Alpha-Methylacyl-CoA racemase: a novel tumor marker over-expressed in several human cancers and their precursor lesions. Am J Surg Pathol (2002) 2.10
Prognostic factors in breast cancer: current and new predictors of metastasis. J Mammary Gland Biol Neoplasia (2001) 2.02
Selective interactions between vertebrate polycomb homologs and the SUV39H1 histone lysine methyltransferase suggest that histone H3-K9 methylation contributes to chromosomal targeting of Polycomb group proteins. Mol Cell Biol (2002) 1.85
Tissue microarray assessment of prostate cancer tumor proliferation in African- American and white men. J Natl Cancer Inst (2000) 1.80
Polycomb group protein complexes: do different complexes regulate distinct target genes? Biochim Biophys Acta (1999) 1.75
Assessing the clinical impact of prognostic factors: when is "statistically significant" clinically useful? Breast Cancer Res Treat (1998) 1.70
Coexpression of BMI-1 and EZH2 polycomb group genes in Reed-Sternberg cells of Hodgkin's disease. Am J Pathol (2000) 1.69
Mammary carcinoma cell lines of high and low metastatic potential differ not in extravasation but in subsequent migration and growth. Clin Exp Metastasis (1994) 1.64
erbB-2 overexpression in human mammary epithelial cells confers growth factor independence. Endocrinology (1999) 1.60
Suberoylanilide hydroxamic acid as a potential therapeutic agent for human breast cancer treatment. Mol Med (2000) 1.56
Anti-invasive, antitumorigenic, and antimetastatic activities of the PHSCN sequence in prostate carcinoma. Cancer Res (2000) 1.54
Invasion of selectively permeable sea urchin embryo basement membranes by metastatic tumor cells, but not by their normal counterparts. Cancer Res (1995) 1.35
Do we need prognostic factors in nodal-negative breast cancer? Arbiter. Eur J Cancer (2000) 1.11
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Control of developmental regulators by Polycomb in human embryonic stem cells. Cell (2006) 28.21
Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med (2004) 27.92
Polycomb complexes repress developmental regulators in murine embryonic stem cells. Nature (2006) 25.90
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Efficient tumour formation by single human melanoma cells. Nature (2008) 16.35
Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature (2005) 15.28
Development of human protein reference database as an initial platform for approaching systems biology in humans. Genome Res (2003) 14.79
American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol (2010) 14.41
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol (2007) 14.29
Integrated genomic characterization of endometrial carcinoma. Nature (2013) 14.29
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
ProbeMatch: rapid alignment of oligonucleotides to genome allowing both gaps and mismatches. Bioinformatics (2009) 13.34
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature (2009) 12.58
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol (2013) 12.57
The mutational landscape of lethal castration-resistant prostate cancer. Nature (2012) 11.82
Transcriptome sequencing to detect gene fusions in cancer. Nature (2009) 11.63
Distinct classes of chromosomal rearrangements create oncogenic ETS gene fusions in prostate cancer. Nature (2007) 10.94
Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles. Neoplasia (2007) 10.74
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
TEAD mediates YAP-dependent gene induction and growth control. Genes Dev (2008) 9.88
Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res (2006) 9.87
Role of histone H3 lysine 27 methylation in X inactivation. Science (2003) 9.85
Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol (2003) 9.72
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci U S A (2004) 9.42
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol (2009) 9.39
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst (2003) 8.66
Integrative molecular concept modeling of prostate cancer progression. Nat Genet (2006) 8.49
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med (2007) 8.02
Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol (2013) 7.97
Use of archived specimens in evaluation of prognostic and predictive biomarkers. J Natl Cancer Inst (2009) 7.95
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science (2008) 7.59
Autoantibody signatures in prostate cancer. N Engl J Med (2005) 7.56
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol (2006) 7.43
Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res (2002) 7.29
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Establishment of histone h3 methylation on the inactive X chromosome requires transient recruitment of Eed-Enx1 polycomb group complexes. Dev Cell (2003) 7.11
Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell (2009) 7.09
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. Cancer Cell (2010) 6.76
Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol (2011) 6.54
Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol (2002) 6.51
The emergence of lncRNAs in cancer biology. Cancer Discov (2011) 6.32
Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol (2005) 6.18
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. J Natl Cancer Inst (2011) 6.11
TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol (2007) 6.09
Recurrent gene fusions in prostate cancer. Nat Rev Cancer (2008) 6.08
Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell (2005) 6.04
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell (2007) 5.99
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst (2005) 5.92
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88